Boehringer Ingelheim Partners with NIPER Raebareli to Advance Pharmaceutical Research and Education in India
核心洞察
Boehringer Ingelheim India (搜索) has signed a memorandum of understanding with NIPER Raebareli (搜索) to establish a framework for academic and research collaboration in pharmaceutical technologies and novel drug delivery systems.
The partnership will provide NIPER access to Boehringer's opnMe (搜索) open science portal and enable joint research initiatives, academic exchanges, and capability-building programs.
This collaboration supports India's transition from a volume-driven pharmaceutical sector to an innovation-focused, research-driven ecosystem aligned with the Viksit Bharat 2047 vision.
Boehringer Ingelheim India (搜索) Private Limited has signed a memorandum of understanding with the National Institute of Pharmaceutical Education and Research (搜索) (NIPER), Raebareli, to advance collaboration in pharmaceutical education and research. The agreement, signed on February 19, 2026, at the Department of Pharmaceuticals (搜索), establishes a comprehensive framework for academic and industry partnership in India's evolving pharmaceutical landscape.
The MoU was formalized in the presence of senior government officials including Shri Manoj Joshi, IAS, Secretary, Department of Pharmaceuticals (搜索), along with Shri Awadhesh Kumar Choudhary, Senior Economic Advisor, and Ms. Anugraha P, Director at the Department of Pharmaceuticals.
Comprehensive Research Framework
The partnership encompasses multiple areas of collaboration, including pharmaceutical technologies, novel drug delivery systems, joint research initiatives, academic exchange programs, and capability-building activities. The agreement also includes NIPER's Centre of Excellence for Novel Drug Delivery Systems (搜索) (CoE-NDDS), positioning the collaboration at the forefront of innovative pharmaceutical research.
A key component of the partnership involves Boehringer Ingelheim providing NIPER Raebareli (搜索) access to opnMe (搜索), the company's open science portal designed to connect researchers and institutions to accelerate scientific progress and healthcare innovation. This digital platform will facilitate enhanced collaboration between academic researchers and industry experts.
Strategic Vision for Innovation
"India is entering an important phase in its pharmaceutical journey, moving from scale-led growth to innovation-led impact," said Meenal Gauri, Managing Director of Boehringer Ingelheim India (搜索). "At Boehringer Ingelheim, we believe progress in healthcare is accelerated when industry, academia, and public institutions come together. This MoU with NIPER Raebareli (搜索) reflects our commitment to strengthening scientific capability and supporting collaborations that can contribute to better health outcomes for patients and communities."
Prof. Shubhini A. Saraf, Director of NIPER Raebareli (搜索), emphasized the partnership's alignment with the institute's mission: "This MoU supports our vision of advancing pharmaceutical education and research while enabling opportunities for students and researchers to contribute to areas of emerging importance such as novel drug delivery systems and community health solutions. We look forward to working with Boehringer Ingelheim to create meaningful opportunities for students and researchers and to contribute to India's innovation ecosystem."
Academic and Scientific Exchange
The collaboration will extend beyond research to include educational initiatives such as symposia, conferences, short-term courses, and scholar engagement programs. These activities are designed to strengthen scientific exchange and create structured pathways for knowledge transfer between academic institutions and industry.
Supporting India's Pharmaceutical Transformation
The partnership aligns with India's broader strategic efforts to transition its pharmaceutical sector from a volume-driven and generic-led model to a more innovation-focused and research-driven ecosystem. This transformation is considered essential for achieving the country's long-term healthcare and innovation goals under the Viksit Bharat 2047 vision.
By creating structured engagement between academic research and industry expertise, the partnership aims to contribute to the development of skilled scientific talent and research pathways that can support more effective and patient-centric healthcare solutions. The collaboration represents a significant step in strengthening industry-academia linkages, which are viewed as key components of India's pharmaceutical sector evolution.